Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 377 across all filing types
Latest filing 2023-11-09 Interim / Quarterly Rep…
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 DELÅRSRAPPORT JANUARI – SEPTEMBER' (Interim Report January-September 2023). It contains comprehensive financial statements, including income statements, balance sheets, cash flow statements, and management commentary for the period. It is clearly a quarterly/interim financial report, not an announcement of a report or a summary. 9M 2023
2023-11-09 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 INTERIM REPORT JANUARY – SEPTEMBER' and contains comprehensive financial statements, including income statements, cash flow statements, and balance sheets for the Immunovia Group. It provides detailed management commentary, key performance indicators, and notes to the financial statements. It is clearly a quarterly/interim financial report, not an announcement or a summary. 9M 2023
2023-11-09 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I IMMUNOVIA AB (PUBL)
Proxy Solicitation & Information Statement Classification · 98% confidence The document is titled "KALLELSE TILL EXTRA BOLAGSSTÄMMA I IMMUNOVIA AB (PUBL)" which translates to "NOTICE OF EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)". The text details the date, time, location, registration procedures, agenda items (including proposals for board member elections and incentive programs), and proposed resolutions for this shareholder meeting. This content directly corresponds to the purpose of a notice for a general meeting, which is often covered by Proxy Solicitation & Information Statement (PSI) materials, or in some contexts, related to AGM materials if it were the Annual General Meeting. Since this is an *Extraordinary* General Meeting (EGM) and the content is the formal notice and proposals, it strongly aligns with the purpose of soliciting shareholder votes and providing necessary information, fitting best under Proxy Solicitation & Information Statement (PSI). While it is a notice, the length and detail suggest it is more than just a simple announcement (RPA/RNS) and contains the substance typically found in proxy materials.
2023-10-27 Swedish
CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)
AGM Information Classification · 98% confidence The document is explicitly titled "CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)". It details the date, time, location, registration procedures, proposed agenda items (including election of chair, board members, and resolutions on incentive programs), and biographical information for proposed new board members. This content is characteristic of a formal notice sent to shareholders regarding a meeting where key corporate decisions are to be voted upon. The agenda items strongly suggest a meeting convened to make significant corporate governance and compensation decisions, which aligns perfectly with the purpose of a General Meeting notice. Since the document is the notice itself, and it concerns a general meeting, the most appropriate classification is AGM-R (AGM Information), as Extraordinary General Meetings (EGM) fall under the broader category of General Meetings, which AGM-R covers in the provided definitions, especially when compared to DEF 14A (Remuneration) or PSI (Proxy Solicitation), which are related but not the primary document type here.
2023-10-27 English
Valberedning utsedd i Immunovia AB (Publ)
AGM Information Classification · 95% confidence The document is a press release dated October 3, 2023, announcing the composition of the Nomination Committee ('Valberedning') for the upcoming Annual General Meeting (AGM) in 2024. The text details the process for appointing members to the Nomination Committee based on shareholder representation, which is a governance function directly related to the preparation for the AGM and the election of the board. This type of announcement, dealing with the structure and appointment of the body responsible for nominating board members, falls under the scope of corporate governance and board-related matters. While it is an announcement, it is not a general regulatory filing (RNS) or a proxy statement (PSI), but specifically concerns the composition of the body that prepares board nominations. This aligns most closely with Board/Management Information (MANG) or Governance Information (CGR). Since it specifically names the committee responsible for nominating directors for the AGM, it is a key governance announcement. Given the options, 'Governance Information' (CGR) is the most appropriate fit for detailing the structure and appointment rules of the Nomination Committee, which is a core governance mechanism.
2023-10-03 Swedish
Nomination Committee appointed for Immunovia AB (Publ)
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of members to the Nomination Committee for Immunovia AB (Publ), following procedures established at the Annual General Meeting (AGM). This announcement concerns the composition and structure of a key corporate governance body (the Nomination Committee), which is directly related to board oversight and shareholder representation. This fits best under Board/Management Information (MANG) as it details the composition of a committee responsible for nominating board members and executives, or potentially Governance Information (CGR). Since it specifically deals with the appointment of members to a committee that handles board nominations, MANG is the most precise fit, as it relates to management/board structure changes, even if indirect. It is not an AGM presentation (AGM-R), a full report (10-K/IR), or a director's dealing (DIRS).
2023-10-03 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.